《大行報告》大摩上調阿里健康(00241.HK)目標價至21.4元 評級「增持」
摩根士丹利發表報告指,阿里健康(00241.HK)2020財年下半財年的業績好過該行預期,主要是受到直接製藥業務及互聯網醫療服務的強勁增長所帶動。該行將阿里健目標價由原來的14.5元上調至21.4元,此相當預測2022年市銷率的8.6倍,以反映在有利的政策下,在線藥品銷售及互聯網醫療服務的持續增長,維持「增持」投資評級。
該行將阿里健康的2021至2023財年銷售預測上調5至8%,主要是因為疫情後在線藥品銷售會有進一步滲透;4月20日前完成81億元的資產注入及相應的新股發行,以及互聯網醫療領域的增長加快。這意味著公司2020至2022財年的銷售年複合增長率達73%,並會在2022財年達到收支平衡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.